|keynote 028 prostate||1.27||0.4||5303||44|
The KEYNOTE-028 trial is a single-arm, phase Ib basket trial that evaluated pembrolizumab in 20 cohorts of patients with a range of advanced solid tumors positive for programmed death ligand 1 (PD-L1). Exploratory study endpoints included the association between pembrolizumab efficacy and two inflammatory biomarkers and TMB.What is the keykeynote-199 study?
KEYNOTE-199 is a five-cohort, open-label, phase II study. Cohorts 1, 2, and 3 enrolled patients at 85 sites in 21 countries. The trial was conducted in accordance with Good Clinical Practice and the protocol and its amendments, which were approved by the appropriate ethics body at each center.What is the Phase II keynote-199 study of mCRPC?
The phase II KEYNOTE-199 study included three cohorts of patients with mCRPC treated with docetaxel and one or more targeted endocrine therapies. Cohorts 1 and 2 enrolled patients with RECIST-measurable PD-L1–positive and PD-L1–negative disease, respectively. Cohort 3 enrolled patients with bone-predominant disease, regardless of PD-L1 expression.Is pembrolizumab effective against metastatic castration-resistant prostate cancer?
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study ; ... Pembrolizumab has previously shown antitumor activity against programmed death ligand 1 (PD-L1)–positive metastatic castration-resistant prostate cancer (mCRPC).